top of page
homeimage_smaller_edited_edited.png

Delivering Therapeutic Proteins Via Neuronal Circuitry

Intraneuronal Drug Delivery | Biobetter | Biodefense

ABOUT

CytoDel is a preclinical stage biopharmaceutical company developing recombinant botulinum toxin (rBoT) derivatives that can deliver therapeutics to the neuronal cytoplasm

TECHNOLOGY

CytoDel’s rBoT platform enables the creation of a new class of antibody fusion proteins, that specifically deliver their payload to previously inaccessible targets in the neuronal cytoplasm

PROGRAMS

Our lead program utilizes intraneuronal delivery for Biodefense, and additionally, CytoDel is developing programs for the treatment of nervous system disorders and chronic pain. A second program is a Biobetter BoT offering an improved safety margin and outcomes for the treatment of large muscles and muscle groups.

CytoDel, Inc. ®
423 W 127th Street, New York, NY 10027
info@cytodel.com

bottom of page